- Home
- ECVT vs CDNA Comparison
ECVT vs CDNA Comparison
Compare ECVT & CDNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ECVT | CDNA |
|---|---|---|
| Founded | 1935 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Medical Specialities |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 2.6B |
| IPO Year | 2017 | 2007 |
Fundamental Metrics
Financial Performance| Metric | ECVT | CDNA |
|---|---|---|
| Price | $10.39 | $54.33 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 6 |
| Target Price | $14.00 | ★ $28.00 |
| AVG Volume (30 Days) | ★ 1.1M | 1.0M |
| Earning Date | 05-05-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | 0.11 | ★ 2.13 |
| Revenue | ★ $723,515,000.00 | $48,324,000.00 |
| Revenue This Year | $29.07 | $16.01 |
| Revenue Next Year | $6.71 | $11.31 |
| P/E Ratio | $94.77 | ★ $25.21 |
| Revenue Growth | 2.70 | ★ 18.93 |
| 52 Week Low | $7.41 | $13.95 |
| 52 Week High | $15.09 | $55.16 |
Technical Indicators
Market Signals| Indicator | ECVT | CDNA |
|---|---|---|
| Relative Strength Index (RSI) | 47.86 | 68.92 |
| Support Level | $9.81 | $45.74 |
| Resistance Level | $10.61 | N/A |
| Average True Range (ATR) | 0.29 | 2.02 |
| MACD | 0.10 | -0.03 |
| Stochastic Oscillator | 56.15 | 81.33 |
Price Performance
Historical ComparisonAbout ECVT Ecovyst Inc.
Ecovyst Inc is an integrated and provider of materials, specialty catalysts and services. Its products contribute to lower emissions and cleaner air, higher fuel efficiency and cleaner fuels, and key enablers to advance transition to clean energy. The company has one operating segment. The Company's single reportable segment, Ecoservices, derives its revenue through the sale of virgin and regenerated sulfuric acid products and services.
About CDNA CareDx Inc.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically it generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.